<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03799133</url>
  </required_header>
  <id_info>
    <org_study_id>ISM_VC_01_17</org_study_id>
    <secondary_id>17-1025</secondary_id>
    <nct_id>NCT03799133</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of the Gastric Reactance (XL) in Patients Post-operated of Elective Cardiac Surgery</brief_title>
  <official_title>Safety and Efficacy of the Gastric Reactance (XL) in the Prediction of Morbimortality in Patients Post-operated of Elective Cardiac Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Critical Perfusion Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto Nacional de Cardiologia Ignacio Chavez</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Council of Science and Technology, Mexico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gerbera Capital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Alandra Medical SAPI de CV</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Critical Perfusion Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the safety and effectiveness of the XL trend measured by Florence (Critical
      Perfusion Inc, Palo Alto, California) in the prediction of morbimortality of Mexican patients
      post-operated of elective cardiovascular surgery.

      Hypothesis: 1. The gastric reactance measurement (XL) correlates with the morbimortality
      (postoperatory shock, excessive bleeding, vasoplegic syndrome and death) and with the risk
      predictors (APACHE II, STS, SOFA, and EUROSCORE II) with patients post-operated of elective
      cardiac surgery. 2. It is possible to identify the cut-off point of the values of the gastric
      reactance (XL) as a predictive tool of morbimortality in patients post-operated of elective
      cardiac surgery. 3. The gastric reactance (XL) is a safe measurement to patients undergoing
      cardiac surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A maximum of 35 patients with age greater or equal to 18 years with elective surgery
      (valvular surgery, revascularization, or a combination of both) that comply with the
      inclusion/exclusion criteria of this protocol will be enrolled.

      Investigational device: Florence (Gastric Impedance Spectrometer System or ISMO). Comparative
      with Risk scales SOFA, APACHE II, STS, Euroscore II, hemodynamic variables, lactate and mixed
      venous saturation.

      The Florence catheter will be placed at the beginning of the surgery and up to 72 hours in
      ICU.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 26, 2018</start_date>
  <completion_date type="Actual">December 28, 2019</completion_date>
  <primary_completion_date type="Actual">December 28, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Eligible patients will be placed the Florence catheter.</intervention_model_description>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation between gastric reactance (XL) and morbimortality and risk predictors</measure>
    <time_frame>72 hours</time_frame>
    <description>Multivariate analysis to observe variability between different events according to data distribution to determine how is affecting the risk scales, hemodynamic variables, lactate and mixed venous oxygen saturation, morbidity and mortality with central gastric reactance (XL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sensibility and specificity of the collected variables</measure>
    <time_frame>72 hours</time_frame>
    <description>ROC curves will be calculated to determine sensibility and specificity of the variables.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events tracing with the use of Florence catheter</measure>
    <time_frame>30 days</time_frame>
    <description>Serious Adverse Device Effects and Adverse Events assessment to evaluate device safety.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlations between XL measurements and medication</measure>
    <time_frame>72 hours</time_frame>
    <description>Multivariate analysis to observe variability between different events according to data distribution to determine how is affecting XL with amines, proton-pump inhibitors, and anesthesia medications.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlations between laboratory parameters and XL</measure>
    <time_frame>72 hours</time_frame>
    <description>Multivariate analysis to observe variability between different events according to data distribution to determine how is affecting XL with laboratory parameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Usability of Florence device in a real environment.</measure>
    <time_frame>72 hours</time_frame>
    <description>Questionnaire for the nurse and/or the physician regarding the use of Florence device at the Operating Room and Intensive Care Unit.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Cardiac Failure</condition>
  <condition>Ventricular Dysfunction</condition>
  <condition>Valvular Heart Disease</condition>
  <arm_group>
    <arm_group_label>Patients with Florence device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with the Florence catheter placed and connected to the Florence monitor to measure XL trend.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Florence device</intervention_name>
    <description>The Florence catheter will be placed at the beginning of the surgery and up to 72 hours in ICU.</description>
    <arm_group_label>Patients with Florence device</arm_group_label>
    <other_name>ISMO</other_name>
    <other_name>Gastric Impedance Spectrometer System</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women and men within an age equal or greater than 18 years old.

          -  Subjects scheduled to an elective cardiac surgery for valvular surgery,
             revascularization or a combination of both.

          -  Subjects compliant with the indication to be placed a floating pulmonary artery
             catheter.

          -  Marks results previous to surgery: STS mortality risk equal or greater than 6% of the
             day before or Euro Score II with a mortality risk equal or greater than 6% or left
             ventricle ejection fraction (LVEF/FEVI) less than 45% (patients with cardiac failure
             or right ventricle dysfunction or a combination of both), tricuspid annular plane
             systolic excursion (TAPSE) less than 17 mm, peak systolic velocity of tricuspid
             lateral ring measured by Tissue Doppler (LVOT/TSVI) less than 0.1 m/s; patient with
             elective surgery of: aortic and mitral valve replacement or aortic and mitral valve
             replacement + tricuspid valve plasty or aortic valve replacement + mitral valve plasty
             or mitral valve replacement + tricuspid valve plasty or aortic, mitral and tricuspid
             valve replacement or aortic valve replacement + tricuspid valve plasty or double valve
             replacement (any combination) + revascularization or aortic valve replacement +
             revascularization + mitral valve plasty.

          -  Subject is not enrolled in another investigational protocol.

          -  Informed consent has been signed of acceptance by the subject before study procedures.

          -  Subject in sinus rhythm before surgery.

        Exclusion Criteria:

          -  Subjects with records of recent digestive tube bleeding (last 30 days).

          -  Paraplegic or hemiplegic subjects.

          -  Subjects with congenital background (interauricular communication, ventricular atrial
             channel, coarctation of the aorta, persistent arterial duct, pulmonary stenosis,
             ventricular septal defect, tetralogy of fallot, total or partial anomalous pulmonary
             venous drainage, transposition of the great vessels, tricuspid atresia, arterial
             trunk, etc).

          -  Maxillofacial malformation.

          -  Catheter placement failure.

          -  Known pregnancy or discovered pregnancy after admission (before surgery).

          -  Woman in breastfeeding period.

          -  Subjects not compliant with clinical indication of nasogastric catheter placement or
             contraindicated to place a nasogastric catheter.

          -  Subjects with an implanted pacemaker or permanent defibrillator.

          -  Medication supply that impedes contact between Florence catheter and the gastric
             mucosa (barrier effect) like sucralfate, aluminum hydroxide, bismuth subsalicylate,
             magaldrate, etc.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rolando J. Álvarez Álvarez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Nacional de Cardiologia Ignacio Chavez</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Montserrat Godínez, MSc</last_name>
    <role>Study Director</role>
    <affiliation>Alandra Medical SAPI de CV</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Instituto Nacional de Cardiología Ignacio Chávez</name>
      <address>
        <city>Tlalpan</city>
        <state>Ciudad De México</state>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <link>
    <url>http://www.who.int/mediacentre/factsheets/fs317/es/</url>
    <description>WHO Cardiovascular illness; 2015</description>
  </link>
  <link>
    <url>http://www.who.int/nmh/publications/ncd-action-plan/en/</url>
    <description>WHO. Global action plan for the prevention and control of NCDs 2013-2020; 2013</description>
  </link>
  <link>
    <url>http://www.medigraphic.com/pdfs/cardio/h-2016/hs163a.pdf</url>
    <description>Arias AS, Serrano MEB, Altamirano BD, Ortega MG, Gonzalez GG. Cardiovascular illness: first cause of morbility in a third level hospital. Cardiology Mexican Journal; 2016</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/24055446</url>
    <description>Mittal R, Coopersmith CM. Redefining the gut as the motor of critical illness. Trends in molecular medicine. 2014 Apr;20:214-223</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/23361625</url>
    <description>Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Critical care medicine. 2013 Feb;41:580-637</description>
  </link>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/17285286</url>
    <description>Antonelli M, Levy M, Andrews PJD, Chastre J, Hudson LD, Manthous C, et al. Hemodynamic monitoring in shock and implications for management. International Consensus Conference, Paris, France, 27-28 April 2006. Intensive care medicine. 2007 Apr;33:575-590</description>
  </link>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/15681577</url>
    <description>Nieminen MS, Boehm M, Cowie MR, Drexler H, Filippatos GS, Jondeau G, et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology.</description>
  </link>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/22611136</url>
    <description>McMurray JJV, Adamopoulos S, Anker SD, Auricchio A, Boehm M, Dickstein K, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure2012</description>
  </link>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/11445675</url>
    <description>Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Critical care medicine. 2001 Jul;29:1303-1310</description>
  </link>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/14997295</url>
    <description>Brun-Buisson C, Meshaka P, Pinton P, Vallet B, Group ES. EPISEPSIS: a reappraisal of the epidemiology and outcome of severe sepsis in French intensive care units. Intensive care medicine. 2004 Apr;30:580-588</description>
  </link>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/17323051</url>
    <description>Engel C, Brunkhorst FM, Bone HG, Brunkhorst R, Gerlach H, Grond S, et al. Epidemiology of sepsis in Germany: results from a national prospective multicenter study. Intensive care medicine. 2007 Apr;33:606-618</description>
  </link>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/17414725</url>
    <description>Esteban A, Frutos-Vivar F, Ferguson ND, Penuelas O, Lorente JA, Gordo F, et al. Sepsis incidence and outcome: contrasting the intensive care unit with the hospital ward. Critical care medicine. 2007 May;35:1284-1289</description>
  </link>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4968574/</url>
    <description>Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al.. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3); 2016</description>
  </link>
  <link>
    <url>https://www.nejm.org/doi/full/10.1056/NEJM199904153401504</url>
    <description>Goldberg RJ, Samad NA, Yarzebski J, Gurwitz J, Bigelow C, Gore JM. Temporal trends in cardiogenic shock complicating acute myocardial infarction. The New England journal of medicine. 1999 Apr;340:1162-1168</description>
  </link>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/16046651</url>
    <description>Babaev A, Frederick PD, Pasta DJ, Every N, Sichrovsky T, Hochman JS, et al. Trends in management and outcomes of patients with acute myocardial infarction complicated by cardiogenic shock. JAMA. 2005 Jul;294:448-454</description>
  </link>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/12161222</url>
    <description>Steg PG, Goldberg RJ, Gore JM, Fox KAA, Eagle KA, Flather MD, et al. Baseline characteristics, management practices, and in-hospital outcomes of patients hospitalized with acute coronary syndromes in the Global Registry of Acute Coronary Events (GRACE).</description>
  </link>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/17828438</url>
    <description>Koek HL, Kardaun JWPF, Gevers E, de Bruin A, Reitsma JB, Grobbee DE, et al. Acute myocardial infarction incidence and hospital mortality: routinely collected national data versus linkage of national registers. European Journal of Epidemiology. 2007</description>
  </link>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/11874305</url>
    <description>Roger VL, Jacobsen SJ, Weston SA, Goraya TY, Killian J, Reeder GS, et al. Trends in the incidence and survival of patients with hospitalized myocardial infarction, Olmsted County, Minnesota, 1979 to 1994. Annals of internal medicine. 2002 Mar;136:341-348</description>
  </link>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/12352031</url>
    <description>Geppert A, Steiner A, Zorn G, Delle-Karth G, Koreny M, Haumer M, et al. Multiple organ failure in patients with cardiogenic shock is associated with high plasma levels of interleukin-6. Critical care medicine. 2002 Sep;30:1987-1994</description>
  </link>
  <link>
    <url>https://www.nejm.org/doi/full/10.1056/NEJMoa010307</url>
    <description>Rivers E, Bryant N, Havstad S, Ressler J, Muzzin A, Knoblich B, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. The New England Journal of Medicine. 2001;345(19):1368-1377</description>
  </link>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/20966436</url>
    <description>Hamilton MA, Cecconi M, Rhodes A. A systematic review and meta-analysis on the use of preemptive hemodynamic intervention to improve postoperative outcomes in moderate and high-risk surgical patients. Anesthesia and analgesia. 2011 Jun;112:1392-1402</description>
  </link>
  <link>
    <url>https://jamanetwork.com/journals/jamasurgery/article-abstract/591550</url>
    <description>Carrico CJ, Meakins JL, Marshall JC, Fry D, Maier RV. Multiple-organ-failure syndrome. Archives of surgery (Chicago, Ill : 1960). 1986 Feb;121:196-208</description>
  </link>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/24694282</url>
    <description>Helander HF, Fändriks L. Surface area of the digestive tract - revisited. Scandinavian journal of gastroenterology. 2014 Jun;49:681-689</description>
  </link>
  <link>
    <url>https://www.sciencedirect.com/science/article/pii/S0092867416000532</url>
    <description>Sender R, Fuchs S, Milo R. Are We Really Vastly Outnumbered? Revisiting the Ratio of Bacterial to Host Cells in Humans. Cell. 2016 Jan;164:337-340</description>
  </link>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/25417158</url>
    <description>Thome JJC, Yudanin N, Ohmura Y, Kubota M, Grinshpun B, Sathaliyawala T, et al. Spatial map of human T cell compartmentalization and maintenance over decades of life. Cell. 2014 Nov; 159:814-828</description>
  </link>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/23370829</url>
    <description>Reintam B, Poeze M, Malbrain ML, Björck M, Oudemans-van Straaten H. Starkopf J, et al. Gastrointestinal symptoms during the first week of intensive care are associated with poor outcome: a prospective multicentre study. Intensive Care Medicine. 2013</description>
  </link>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/17577136</url>
    <description>Clark JA, Coopersmith CM. Intestinal crosstalk: a new paradigm for understanding the gut as the &quot;motor&quot; of critical illness. Shock (Augusta, Ga). 2007 Oct; 28:384-393</description>
  </link>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/27016162</url>
    <description>Klingensmith NJ, Coopersmith CM. The Gut as the Motor of Multiple Organ Dysfunction in Critical Illness; 2016</description>
  </link>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/17933153</url>
    <description>van Haren FMP, Sleigh JW, Pickkers P, Van der Hoeven JG. Gastrointestinal perfusion in septic shock. Anaesth Intensive Care. 2007 Oct;35(5):679-694</description>
  </link>
  <link>
    <url>https://www.journalofsurgicalresearch.com/article/S0022-4804(00)95862-1/abstract</url>
    <description>Matheson PJ, Wilson MA, Garrison RN. Regulation of intestinal blood flow. The Journal of surgical research. 2000 Sep;93:182-196</description>
  </link>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/8528108</url>
    <description>McAdams ET, Jossinet J. Tissue impedance: a historical overview. Physiol Meas. 1995 Aug;16(3 Suppl A):A1-13. Historical Article Journal Article</description>
  </link>
  <link>
    <url>http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.516.4685&amp;rep=rep1&amp;type=pdf</url>
    <description>Ivorra A. Bioimpedance monitoring for physicians: an overview; 2003</description>
  </link>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/2662632</url>
    <description>Kim DW. Detection of physiological events by impedance. Yonsei Med J. 1989;30(1):1-11</description>
  </link>
  <link>
    <url>https://ieeexplore.ieee.org/document/4067112</url>
    <description>Grimnes S, Martinsen OG. Comments on &quot;Algorithm for Tissue Ischemia Estimation Based on Electrical Impedance Spectroscopy&quot;. IEEE Transactions on Biomedical Engineering. 2007 Feb;54(2):344-344</description>
  </link>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/9196884</url>
    <description>Rigaud B, Morucci JP, Chauveau N. Bioelectrical impedance techniques in medicine. Part I: Bioimpedance measurement. Second section: impedance spectrometry. Crit Rev Biomed Eng. 1996;24(4-6):257-351</description>
  </link>
  <link>
    <url>https://ieeexplore.ieee.org/document/415187</url>
    <description>Kun S, Peura RA. Tissue ischemia detection using impedance spectroscopy. In: Engineering in Medicine and Biology Society, 1994. Engineering Advances: New Opportunities for Biomedical Engineers. Proceedings of the 16th Annual International Conference</description>
  </link>
  <link>
    <url>https://ieeexplore.ieee.org/document/758768</url>
    <description>Ristic B, Kun S, Peura RA. Muscle tissue ischemia monitoring using impedance spectroscopy: quantitative results of animal studies. In: Engineering in Medicine and Biology Society, 1997. Proceedings of the 19th Annual International Conference of the IEEE.</description>
  </link>
  <link>
    <url>https://www.sciencedirect.com/science/article/pii/S0006349599774163</url>
    <description>Kyle AH, Chan CTO, Minchinton AI. Characterization of Three-Dimensional Tissue Cultures Using Electrical Impedance Spectroscopy. Biophysical Journal. 1999;76(5):2640 - 2648</description>
  </link>
  <link>
    <url>https://www.sciencedirect.com/science/article/pii/S0302459898000798</url>
    <description>Gersing E. Impedance spectroscopy on living tissue for determination of the state of organs. Bioelectrochem Bioenerg. 1998;45:145-49</description>
  </link>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/15798229</url>
    <description>Ivorra A, Genesca M, Sola A, Palacios L, Villa R, Hotter G, et al. Bioimpedance dispersion width as a parameter to monitor living tissues. Physiol Meas. 2005 Apr;26(2):S165-73. Comparative Study Journal Article Research Support, Non-U.S. Gov't</description>
  </link>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/2651001</url>
    <description>Foster KR, Schwan HP. Dielectric properties of tissues and biological materials: a critical review. Critical reviews in biomedical engineering. 1989;17:25-104</description>
  </link>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/11713146</url>
    <description>Rackow EC, O'Neil P, Astiz ME, Carpati CM. Sublingual capnometry and indexes of tissue perfusion in patients with circulatory failure. Chest. 2001 Nov;120:1633-1638</description>
  </link>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/8087035</url>
    <description>Rigaud B, Hamzaoui L, Chauveau N, Granie M, Scotto Di Rinaldi JP, Morucci JP. Tissue characterization by impedance: a multifrequency approach. Physiol Meas. 1994 May;15 Suppl 2a:A13-20</description>
  </link>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/27687052</url>
    <description>Sullivan PG, Wallach JD, Ioannidis JPA. Meta-Analysis Comparing Established Risk Prediction Models (EuroSCORE II, STS Score, and ACEF Score) for Perioperative Mortality During Cardiac Surgery. The American journal of cardiology. 2016 Nov;118:1574-1582</description>
  </link>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/22378855</url>
    <description>Nashef SAM, Roques F, Sharples LD, Nilsson J, Smith C, Goldstone AR, et al. EuroSCORE II. European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery. 2012 Apr;41:734-44; discussion 744-5</description>
  </link>
  <link>
    <url>http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S0188-21982014000100010&amp;nrm=iso</url>
    <description>A GVO. EuroSCORE II: Como se usa en la practica actual. Revista Mexicana de Cardiologia. 2014 03;25:50 - 51</description>
  </link>
  <link>
    <url>http://www.iccueducation.org.uk/uploads/2/3/1/0/23109338/sofa_score.pdf</url>
    <description>Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Societ</description>
  </link>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/9824069</url>
    <description>Vincent JL, de Mendonca A, Cantraine F, Moreno R, Takala J, Suter PM, et al. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on &quot;sepsis-related</description>
  </link>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/10470572</url>
    <description>Moreno R, Vincent JL, Matos R, Mendoca A, Cantraine F, Thijs L, et al. The use of maximum SOFA score to quantify organ dysfunction/failure in intensive care. Results of a prospective, multicentre study. Working Group on Sepsis related Problems</description>
  </link>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/10990106</url>
    <description>de Mendonca A, Vincent JL, Suter PM, Moreno R, Dearden NM, Antonelli M, et al. Acute renal failure in the ICU: risk factors and outcome evaluated by the SOFA score. Intensive care medicine. 2000 Jul;26:915-921</description>
  </link>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/11594901</url>
    <description>Ferreira FL, Bota DP, Bross A, Melot C, Vincent JL. Serial evaluation of the SOFA score to predict outcome in critically ill patients. JAMA. 2001 Oct;286:1754-1758</description>
  </link>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/3928249</url>
    <description>Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Critical care medicine. 1985 Oct;13:818-829</description>
  </link>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/6851607</url>
    <description>NIH. Consensus Development Conference on critical care medicine. Critical care medicine. 1983 Jun;11:466-469</description>
  </link>
  <link>
    <url>http://anesthesiology.pubs.asahq.org/article.aspx?articleid=1960390</url>
    <description>Cullen DJ. Results and costs of intensive care. Anesthesiology. 1977 Aug;47:203-216</description>
  </link>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/8087584</url>
    <description>Chalfin DB, Fein AM. Critical care medicine in managed competition and a managed care environment. New horizons (Baltimore, Md). 1994 Aug;2:275-282</description>
  </link>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/19559823</url>
    <description>O'Brien SM, Shahian DM, Filardo G, Ferraris VA, Haan CK, Rich JB, et al. The Society of Thoracic Surgeons 2008 cardiac surgery risk models: part 2-isolated valve surgery. The Annals of thoracic surgery. 2009 Jul;88:S23-S42</description>
  </link>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/19559822</url>
    <description>Shahian DM, O'Brien SM, Filardo G, Ferraris VA, Haan CK, Rich JB, et al. The Society of Thoracic Surgeons 2008 cardiac surgery risk models: part 1-coronary artery bypass grafting surgery. The Annals of thoracic surgery. 2009 Jul;88:S2-22</description>
  </link>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/19559824</url>
    <description>Shahian DM, O'Brien SM, Filardo G, Ferraris VA, Haan CK, Rich JB, et al. The Society of Thoracic Surgeons 2008 cardiac surgery risk models: part 3-valve plus coronary artery bypass grafting surgery. The Annals of thoracic surgery. 2009 Jul;88:S43-S62</description>
  </link>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/23522221</url>
    <description>Rankin JS, He X, O'Brien SM, Jacobs JP, Welke KF, Filardo G, et al. The Society of Thoracic Surgeons risk model for operative mortality after multiple valve surgery. The Annals of thoracic surgery. 2013 Apr;95:1484-1490</description>
  </link>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>December 20, 2018</study_first_submitted>
  <study_first_submitted_qc>January 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 10, 2019</study_first_posted>
  <last_update_submitted>January 22, 2020</last_update_submitted>
  <last_update_submitted_qc>January 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>gastric reactance</keyword>
  <keyword>elective cardiac surgery</keyword>
  <keyword>morbimortality</keyword>
  <keyword>APACHE II</keyword>
  <keyword>STS</keyword>
  <keyword>SOFA</keyword>
  <keyword>EUROSCORE II</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Ventricular Dysfunction</mesh_term>
    <mesh_term>Heart Valve Diseases</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is no plan to make individual participant data (IPD) available to other researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

